F11 and cancer: Nevertheless, with direct inhibition of FXIa and thrombin, FXI inhibition also includes an off-target effect that might be associated with vasoprotective properties due to protease-activated receptor (PAR) cell signaling modifications as well as other complex diseases such as diabetes, nephropathy, fibrosis and cancer, which may be regulated by PAR [57].